JP2007238637A5 - - Google Patents

Download PDF

Info

Publication number
JP2007238637A5
JP2007238637A5 JP2007170267A JP2007170267A JP2007238637A5 JP 2007238637 A5 JP2007238637 A5 JP 2007238637A5 JP 2007170267 A JP2007170267 A JP 2007170267A JP 2007170267 A JP2007170267 A JP 2007170267A JP 2007238637 A5 JP2007238637 A5 JP 2007238637A5
Authority
JP
Japan
Prior art keywords
solid oral
preparation according
oral preparation
compressed solid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007170267A
Other languages
English (en)
Japanese (ja)
Other versions
JP4969338B2 (ja
JP2007238637A (ja
Filing date
Publication date
Priority claimed from GBGB9613470.5A external-priority patent/GB9613470D0/en
Application filed filed Critical
Publication of JP2007238637A publication Critical patent/JP2007238637A/ja
Publication of JP2007238637A5 publication Critical patent/JP2007238637A5/ja
Application granted granted Critical
Publication of JP4969338B2 publication Critical patent/JP4969338B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007170267A 1996-06-27 2007-06-28 バルサルタンの固体経口剤形 Expired - Lifetime JP4969338B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9613470.5 1996-06-27
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003014987A Division JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270429A Division JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形

Publications (3)

Publication Number Publication Date
JP2007238637A JP2007238637A (ja) 2007-09-20
JP2007238637A5 true JP2007238637A5 (enExample) 2010-04-22
JP4969338B2 JP4969338B2 (ja) 2012-07-04

Family

ID=10795969

Family Applications (5)

Application Number Title Priority Date Filing Date
JP10502269A Pending JP2000506540A (ja) 1996-06-27 1997-06-18 バルサルタンの固体経口剤形
JP2003014987A Withdrawn JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形
JP2007170267A Expired - Lifetime JP4969338B2 (ja) 1996-06-27 2007-06-28 バルサルタンの固体経口剤形
JP2011270429A Withdrawn JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形
JP2013221985A Pending JP2014012747A (ja) 1996-06-27 2013-10-25 バルサルタンの固体経口剤形

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP10502269A Pending JP2000506540A (ja) 1996-06-27 1997-06-18 バルサルタンの固体経口剤形
JP2003014987A Withdrawn JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011270429A Withdrawn JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形
JP2013221985A Pending JP2014012747A (ja) 1996-06-27 2013-10-25 バルサルタンの固体経口剤形

Country Status (32)

Country Link
US (3) US6294197B1 (enExample)
EP (7) EP1767206B1 (enExample)
JP (5) JP2000506540A (enExample)
KR (6) KR101208430B1 (enExample)
CN (3) CN1133427C (enExample)
AR (2) AR008618A1 (enExample)
AT (3) ATE371449T1 (enExample)
BR (1) BR9709956A (enExample)
CA (2) CA2673462C (enExample)
CO (1) CO4870755A1 (enExample)
CY (1) CY2553B1 (enExample)
CZ (1) CZ296850B6 (enExample)
DE (3) DE69738089T2 (enExample)
DK (3) DK1410797T3 (enExample)
ES (3) ES2231873T3 (enExample)
GB (1) GB9613470D0 (enExample)
HU (1) HU229134B1 (enExample)
ID (1) ID17553A (enExample)
IL (2) IL127564A0 (enExample)
MY (3) MY123149A (enExample)
NO (2) NO317181B1 (enExample)
NZ (2) NZ333385A (enExample)
PE (1) PE87498A1 (enExample)
PL (2) PL188271B1 (enExample)
PT (3) PT914119E (enExample)
RU (5) RU2294743C2 (enExample)
SI (2) SI1410797T1 (enExample)
SK (1) SK285902B6 (enExample)
TR (1) TR199802698T2 (enExample)
TW (1) TW473394B (enExample)
WO (1) WO1997049394A2 (enExample)
ZA (1) ZA975673B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
SK11902000A3 (sk) * 1998-03-04 2001-02-12 Takeda Chemical Industries, Ltd. Prostriedok s predĺženým uvoľňovaním pre antagonistu angiotenzínu ii, jeho príprava a použitie
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
DE69936992T2 (de) * 1998-07-10 2008-03-06 Novartis Pharma Ag Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
BR9916576A (pt) 1998-12-23 2001-10-02 Novartis Ag Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2
CZ20012682A3 (cs) * 1999-01-26 2001-10-17 Novartis Ag Pouľití antagonistů receptoru angiotensinu II pro léčení akutního infarktu myokardu
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
DE10066408B4 (de) * 2000-03-24 2010-03-18 3M Espe Dental Ag Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005041941A2 (en) * 2003-11-03 2005-05-12 Zentiva, A.S. Valsartan containing formulation
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
US7528258B2 (en) 2004-09-02 2009-05-05 Teva Pharmaceutical Industries Ltd Preparation of olmesartan medoxomil
EP1799196B1 (en) * 2004-10-08 2016-06-22 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080050605A1 (en) * 2004-10-15 2008-02-28 Rapp Knut M Pan Coating Process
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EA012392B1 (ru) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
EP1982711A1 (en) * 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
WO2007005967A2 (en) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US20080227836A1 (en) * 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2007385A4 (en) * 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
MX2008015621A (es) 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
JP2010508266A (ja) * 2006-10-30 2010-03-18 ハナル ファーマシューティカル カンパニー リミテッド チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
EP2139473A1 (en) * 2007-03-29 2010-01-06 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
JP2010540547A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー アリスキレンおよびバルサルタンのガレヌス製剤
RU2487710C2 (ru) * 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
MY153730A (en) 2007-11-06 2015-03-13 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
US8785432B2 (en) * 2007-12-31 2014-07-22 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
CA2713581A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Valsartan solid oral dosage forms and methods of making such formulations
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
RU2398570C1 (ru) * 2009-04-17 2010-09-10 Илья Николаевич Медведев Способ снижения содержания микровезикул в крови при стабильной стенокардии напряжения i-ii функционального класса с артериальной гипертонией
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
BR112014015620A8 (pt) 2011-12-26 2017-07-04 Novartis Ag comprimidos e agentes revestidos a seco
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
WO2014038895A1 (ko) * 2012-09-06 2014-03-13 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
JPH06501475A (ja) * 1990-09-28 1994-02-17 メルク　エンド　カンパニー　インコーポレーテッド イブプロフェン−利尿剤の組み合わせ
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
ZA931063B (en) 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
AU5745394A (en) 1992-12-30 1994-08-15 Fmc Corporation Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
PL316259A1 (en) * 1994-03-17 1997-01-06 Ciba Geigy Ag Treatment of diabetic nephropathy with valsartan
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Similar Documents

Publication Publication Date Title
JP2007238637A5 (enExample)
JP2003231634A5 (enExample)
JP2011037832A5 (enExample)
FI4159205T3 (fi) Uudenlainen farmaseuttinen koostumus
US8435564B2 (en) Pharmaceutical compositions comprising brivaracetam
JP2010132654A5 (enExample)
JP2018507200A5 (enExample)
HRP20161262T1 (hr) Tablete ulipristal acetata
JP2010536849A5 (enExample)
JP2010047612A5 (enExample)
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
JP2006077018A5 (enExample)
JP2008501025A5 (enExample)
JP2009537554A5 (enExample)
IL305908B2 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
FI3182975T3 (fi) Rukaparibin suuren annosvahvuuden tabletteja
JP2018162255A5 (enExample)
MX2012015091A (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol- 2-il]-1h-quinolin-2-ona.
WO2011147026A3 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
JP2006514100A5 (enExample)
JP2011500811A5 (enExample)
JP2019526591A5 (enExample)
JP2019511465A5 (enExample)
JP2008515980A5 (enExample)
JP2005535582A5 (enExample)